scispace - formally typeset
H

Hillary A. Keenan

Researcher at Joslin Diabetes Center

Publications -  45
Citations -  1325

Hillary A. Keenan is an academic researcher from Joslin Diabetes Center. The author has contributed to research in topics: Diabetes mellitus & Type 1 diabetes. The author has an hindex of 15, co-authored 42 publications receiving 1063 citations. Previous affiliations of Hillary A. Keenan include Mount Sinai Hospital, Toronto & Genzyme.

Papers
More filters
Journal ArticleDOI

Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study

TL;DR: Demonstration of persistence and function of insulin-producing pancreatic cells suggests the possibility of a steady state of turnover in which stimuli to enhance endogenous β cells could be a viable therapeutic approach in a significant number of patients with type 1 diabetes, even for those with chronic duration.
Journal ArticleDOI

Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study.

TL;DR: The prevalence of complications and associated risk factors in a large number of individuals who have been insulin dependent for ≥50 years and who were awarded the Joslin Medal between 1997 and 2003 are characterized.
Journal ArticleDOI

The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients.

TL;DR: It is concluded that long-term treatment with 1,800 IU of vitamin E has no beneficial effects on endothelial or left ventricular function in diabetic patients and the use of high dosage vitamin E cannot be recommended.
Journal ArticleDOI

PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts

TL;DR: Pharmacologic inhibition and siRNA-mediated knockdown of PKCδ or expression of a dominant-negative isoform restored insulin signaling of p-AKT and VEGF expression in vitro and improved wound healing in vivo and suggest PKC δ inhibition as a potential therapy to improve wounds healing in diabetic patients.